替考拉宁与万古霉素随机对照多中心临床研究  

Multicenter Randomized Controlled Clinical Trial On Teicoplanin Versus Vancomycin

作　　者：吕芳芳[1] 周志慧[1] 俞云松[1] 郑经川[1] 陈亚岗[1] 顾俊明[2] 王慧玲[2] 霍丽[2] 李卓[2] 薛欣[2] 熊盛道[3] 刘谨[3] 赵建平[3] 徐永建[3] 张珍祥[3] 

机构地区：[1]浙江大学医学院附属一院,杭州310003 [2]大连医科大学附属二院,大连116000 [3]华中科技大学同济医院,武汉430000

出　　处：《中国临床药理学杂志》2002年第4期243-246,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的:评价替考拉宁治疗下呼吸道革兰阳性菌感染的疗效和安全性。方法:给药方案为试验药替考拉宁,第一日每次400mg,qd,此后每次200mg,qd;重度感染第一日每次400mg,q12h,此后每次400mg,qd。对照药万古霉素,每次0、5g,q8h。重度感染每次1.0g,q12h。均为静脉滴注。疗程7～14d。结果:试验药组和对照药组有效率分别为87.10％（54/62）及90.32％（56/62）,痊愈率分别为74.19％（46/62）及61.29％（38/62）,细菌清除率分别为94.74％（54/57）及88.52％（54/61）,药物不良反应发生率分别为11.29％（7/62）及6.45％（4/62）。上述两组的各项结果经统计学处理,均无显著性差异（P>0.05）。结论:替考拉宁对革兰阳性菌抗菌活性强,临床疗效佳,药物不良反应轻微,对革兰阳性菌引起的中、重度感染安全有效。OBJECTIVE: To Evaluate the efficacy and safety of teicoplanin. METHODS: The patients received teicoplanin intravenously once daily at 400mg in the first day, 200mg from the second day and the doses were double for the patients with severe infections, or vancomycin at 0.5g three times daily and 1.0g twice daily for the patients with severe infections. The treatment duration was 7-14 days. RESULTS: The effective rate and cure rate were 87.10% (54/62) and 74.19%(46/62)in teicoplanin group, while in vancomycin group were 90.32%(56/62)and 61.29%(38/62) respectively. The bacterial elimination rate was 94.74%(54/57) in teicoplanin group and 88.52%(54/61) in vancomycin group. Adverse reactions occurred in 11.29%(7/62) of patients in teicoplanin group and 6.45%(4/62) in vancomycin group. There were no statistically differences between the two groups. CONCLUSION: Teicoplanin is an effective and safe agent for treating moderate and severe gram positive bacterial infections.

关 键 词：替考拉宁 万古霉素 下呼吸道感染 随机对照临床试验 疗效 安全性 不良反应 

分 类 号：R560.5[医药卫生—呼吸系统] R978.1[医药卫生—内科学]